A retrospective study of the efficacy and safety of naldemedine for opioid-induced constipation in thoracic cancer patients

Hisao Imai1,2 | Yukiyoshi Fujita3 | Eriko Hiruta3 | Takashi Masuno4 | Shigeki Yamazaki5 | Hajime Tanaka6 | Teruhiko Kamiya7 | Mitsuru Sandoh8 | Satoshi Takei9 | Kazuya Arai10 | Hiromi Nishiba11,12 | Junnosuke Mogi13 | Kyoichi Kaira2 | Koichi Minato1

1Division of Respiratory Medicine, Gunma Prefectural Cancer Center, Ota, Japan
2Department of Respiratory Medicine, Comprehensive Cancer Center, International Medical Center, Saitama Medical University, Hidaka, Japan
3Division of Pharmacy, Gunma Prefectural Cancer Center, Ota, Japan
4Division of Pharmacy, Fujioka General Hospital, Fujioka, Japan
5Division of Pharmacy, Kiryu Kosei General Hospital, Kiryu, Japan
6Division of Pharmacy, Haramachi Red Cross Hospital, Higashiagatsuma-machi, Agatsuma-gun, Japan
7Department of Pharmacy, Tatebayashi Kosei General Hospital, Tatebayashi, Japan
8Division of Pharmacy, Ota Memorial Hospital, Ota, Japan
9Division of Pharmacy, Tone Central Hospital, Numata, Japan
10Division of Pharmacy, Gunma Saiseikai Maebashi Hospital, Maebashi, Japan
11Division of Pharmacy, Japan Community Health Care Organization (JCHO) Gunma Chuo Hospital, Maebashi, Japan
12Graduate School of Pharmaceutical Sciences, Takasaki University of Health and Welfare, Takasaki, Japan
13Division of Pharmacy, Hidaka Hospital, Takasaki, Japan

Correspondence
Hisao Imai, Department of Respiratory Medicine, Comprehensive Cancer Center, International Medical Center, Saitama Medical University, 1397-1 Yamane, Hidaka-City, Saitama 350-1298, Japan.
Email: m06701014@gunma-u.ac.jp

Abstract
Background: We conducted a multicenter, retrospective study on the efficacy and safety of naldemedine in thoracic cancer patients using opioids in clinical practice.
Methods: We retrospectively evaluated thoracic cancer patients treated with naldemedine at 10 institutions in Japan. Clinical data of patients administered naldemedine between June 2017 and August 2019 were extracted from electronic medical records. Inclusion criteria were as follows: (i) patients hospitalized for at least seven days before and after naldemedine administration, and (ii) those whose frequency of defecation was entered in the medical records.

Results: Forty patients were analyzed, and defecation frequency was observed for at least seven days before and after naldemedine administration. The response rate was 65.0% (95% CI: 50.2%–79.7%). The number of defecations increased significantly after naldemedine administration in the overall population, as well as among only those who defecated <3 times/week before naldemedine administration, and those that were administered ≥30 mg/day of morphine equivalent. Diarrhea was the most common adverse event in all grades, occurring in 11 patients (27.5%), of which 9 (81.8%) were grade 1 or 2. None of the patients experienced grade 4 or higher adverse events.

Conclusion: The efficacy and safety of naldemedine for thoracic cancer patients in clinical practice were comparable with those of prospective studies, which suggest that naldemedine may be effective and feasible for most thoracic cancer patients.
INTRODUCTION

Thoracic malignancies include lung cancer, thymic epithelial tumors, and malignant pleural mesothelioma. Lung cancer accounts for a majority of thoracic cancers and is the most common cause of cancer-related mortalities globally. As patients with lung cancer frequently experience significant pain, a better understanding of pain management strategies for this patient population is vital. Opioids are widely used as the standard treatment for moderate-to-severe cancer pain. These drugs effectively treat cancer pain but are often limited by adverse effects that negatively impact the quality of life, sometimes leading to their discontinuation.

Opioid-induced constipation (OIC) is one of the most frequent adverse events in patients using opioids and, without prophylaxis, occurs in more than 50% of patients using opioids. It has been reported that most opioid analgesics can cause OIC, although the rate of occurrence varies according to the type of drug and route of administration. Unlike other adverse events such as nausea and vomiting, continued administration of opioids has been reported not to increase the occurrence of OIC. Prolonged constipation increases the risk of abdominal pain, nausea, vomiting, anorexia, and delirium. These adverse events not only impair the quality of life but also create an obstacle in pain management by inhibiting the use of analgesic medications and preventing the use of rescue. Therefore, control of OIC is important for maintaining the quality of life of patients using opioids to treat cancer-related pain. OIC, characterized as functional constipation, has been defined as a change from baseline bowel habits and defecation patterns following the initiation of opioid therapy.

A recent study evaluated patterns of laxative prescription in patients with lung cancer using opioids. In the study, almost 90% of patients received inadequate or inappropriate OIC prophylaxis. Using the international Rome IV diagnostic criteria for OIC, a survey in Japan reported the incidence of OIC to be 56%. Another Japanese survey using the same criteria showed a 47.8% incidence of OIC in lung cancer patients.

Opioids exert their analgesic effects primarily by activating opioid receptors in the central nervous system. The activation of μ-opioid receptors in the intestinal tract suppresses normal bowel movement, and opioid-induced intestinal dysfunction begins soon after opioid administration. Naldemedine is a peripherally acting μ-opioid receptor antagonist that improves OIC by binding to opioid receptors in the gastrointestinal tract. This antagonist normalizes intestinal function by inhibiting the binding of opioids to the enteric nervous system without decreasing the analgesic effect of opioids. The efficacy and safety of naldemedine in cancer patients have been reported in randomized phase III trials, such as COMPOSE-4 and COMPOSE-5. Major toxicities included diarrhea (19.6%), malaise (4.1%), vomiting (3.1%), and decreased appetite (3.1%), and 9.3% of the participants discontinued the drug due to adverse events.

The incidence of OIC in patients with thoracic cancers, especially lung cancer, has been reported to be approximately 50%. Furthermore, OIC can occur quickly after opioid administration in patients with lung cancer, adversely impacting the quality of life. However, previous phase III trials included carefully selected participants (e.g., Eastern Cooperative Oncology Group performance status [ECOG-PS] ≤ 2, and a cancer condition expected to remain stable for the extent of the study), and data on predictive factors or the detailed course of adverse events were lacking for patients with thoracic cancer. We previously conducted a survey on the use of naldemedine in clinical practice, but there was insufficient evidence of its efficacy in thoracic cancer. Specifically, there are insufficient data from clinical practice involving patients with thoracic cancer who have poor performance status (PS) or those that are elderly. Therefore, we examined whether it is effective and safe to treat OIC in clinical practice in patients with thoracic cancer, including those with poor PS and those that are elderly. Thus, we conducted a multicenter, retrospective study on the efficacy and safety of naldemedine in patients with thoracic cancer using opioids in clinical practice.

METHODS

Patients

This multicenter, retrospective study of thoracic cancer patients treated with naldemedine was conducted among 10 institutions in Japan. The data of patients administered naldemedine between June 7, 2017, and August 31, 2019, were extracted from electronic medical records. Eligible patients were identified using electronic medical charts and pharmacy databases. Patients were included if they met the following criteria: (i) pathologically or cytologically diagnosed with a thoracic malignancy; (ii) naldemedine treatment initiated during hospitalization; (iii) naldemedine used in combination with opioids; and (iv) hospitalized for at least seven days before and after naldemedine administration. The frequency of defecation was noted in the medical records. Eighty-three thoracic cancer patients who received naldemedine for the first time in conjunction with opioids during hospitalization were identified. Of those eligible patients, 43 patients who could not be observed for at least seven days before and after the start of naldemedine administration were excluded. Finally, 40 patients were included in the analysis (Figure S1). The data of 40 patients in current analysis are part of previously described. We reviewed patient charts to collect data regarding baseline characteristics and responses to naldemedine. The study design was
approved by the institutional review board of each participating institution, and the requirement for informed consent was waived owing to the retrospective nature of the study. However, the opportunity to refuse to participate through an opt-out method was guaranteed.

### Treatment

The patients had not previously received naldemedine. In the current study, 0.2 mg of naldemedine was administered orally once a day with opioids. This treatment was continued until the occurrence of unacceptable toxicity.

### TABLE 1 Patient characteristics

| Characteristic                                    | N  =  40 |
|--------------------------------------------------|----------|
| Sex                                              | 30 / 10  |
| Male/female                                      |          |
| Median age at treatment (years) [range]          | 71 [38–88]|
| Performance status (PS)                          |          |
| 0 / 1 / 2 / 3 / 4                                | 5 / 5 / 6 / 17 / 7 |
| Primary tumor                                    |          |
| Lung cancer/malignant mesothelioma               | 39 / 1   |
| Treatment before and during naldemedine          |          |
| administration\(^a\)                            |          |
| Anticancer agents\(^b\)                         | 11       |
| Thoracic radiotherapy                            | 9        |
| Supportive care alone                            | 20       |
| Central nervous system metastasis                |          |
| Yes/No                                           | 10 / 30  |
| Peritonitis                                      |          |
| Yes/No                                           | 1 / 39   |
| Gastrointestinal obstruction                     |          |
| Yes/No                                           | 0 / 40   |
| History of abdominal surgery before starting     |          |
| naldemedine                                     |          |
| Yes/No                                           | 8 / 32   |
| History of radiation to the abdomen and pelvic   |          |
| region before starting naldemedine              |          |
| Yes/No                                           | 7 / 33   |
| Presence of diabetes mellitus                    |          |
| Yes/No                                           | 6 / 34   |
| Discontinuation of naldemedine within 7 days     |          |
| Yes/No                                           | 7 / 33   |
| Use of laxatives before starting naldemedine     |          |
| administration                                    |          |
| Yes/No                                           | 36 / 4   |
| Use of laxatives after starting naldemedine      |          |
| administration                                    |          |
| Yes/No                                           | 36 / 4   |
| Regular use of antiemetic medication after       |          |
| initiation of naldemedine                       |          |
| Yes/No or unknown                                | 10 / 30  |
| Abbreviated use of antiemetic agents after       |          |
| starting naldemedine                             |          |
| Yes/No or unknown                                | 8 / 32   |
| Survival status at data cutoff date              |          |
| Death/Alive                                       | 36 / 4   |
| Period to death from naldemedine initiation      |          |
| Median period (days) [range]                     | 33.5 [9–578]|

\(^a\)Within 3 weeks before starting naldemedine administration.

\(^b\)Detailed breakdown of anticancer agents therapy. The following treatment regimens were included: Carboplatin + paclitaxel 2, cisplatin + vinorelbine 1, cisplatin + pemetrexed 1, docetaxel + ramucirumab 1, gefitinib 1, alectinib 1, S-1 1, pembrolizumab 2, nivolumab.

### TABLE 2 Administration of opioids, laxatives, and antiemetic agents

| Daily dose of opioids (mg)\(^a\) | N   | (%)  |
|----------------------------------|-----|------|
| <30                              | 14  | 35.0 |
| 30–49                            | 16  | 40.0 |
| 50–99                            | 5   | 12.5 |
| ≥100                             | 5   | 12.5 |

Regular use of opioids

| Oxycodeine                        | 22  | 55.0 |
| Morphine                          | 6   | 15.0 |
| Fentanyl                          | 8   | 20.0 |
| Hydromorphone                     | 4   | 10.0 |

Days from first opioid administration to initial naldemedine use (days)

| Days from first opioid administration (days) | N   | (%)  |
|---------------------------------------------|-----|------|
| <4                                          | 2   | 5.0  |
| 4–7                                         | 1   | 2.5  |
| 8–14                                        | 16  | 40.0 |
| 15–28                                       | 7   | 17.5 |
| 29–99                                       | 8   | 20.0 |
| ≥100                                        | 6   | 15.0 |

Drugs of concomitant laxatives\(^b\)

| Magnesium oxide                     | 29  | 72.5 |
| Sennoside                           | 10  | 25.0 |
| Bisacodyl                           | 4   | 10.0 |
| Lubiprostone                        | 3   | 7.5  |
| Sodium picosulfate hydrate          | 1   | 2.5  |
| Sodium bicarbonate, sodium dihydrogen phosphate anhydrous suppository | 6 | 15.0 |
| Others                              | 1   | 2.5  |

Drugs of concomitant antiemetic (regular and abbreviated) use\(^b\)

| Metoclopramide                      | 7   | 17.5 |
| Domperidone                         | 1   | 2.5  |
| Prochlorperazine                     | 5   | 12.5 |
| Olanzapine                          | 2   | 5.0  |
| Others                              | 3   | 7.5  |

\(^a\)Oral morphine equivalent to regular opioids.

\(^b\)Total number of patients.
withdrawal of consent, or an attending physician judged termination to be necessary. The initiation and termination of naldemedine were decided by each attending physician.

**Assessment of treatment efficacy**

We evaluated the number of defecations (times/week) seven days before and after naldemedine administration. A responder was defined as a patient with three or more defecations/week in the first seven days after naldemedine initiation and an increase of one or more defecations/week from the baseline. The baseline was the number of defecations during the week before naldemedine initiation. Adverse events were graded using the Common Terminology Criteria for Adverse Events version 5.0.

**Statistical analysis**

Categorical variables were analyzed using Fisher’s exact test. The Wilcoxon signed-rank test was used to check normality and equal variances and test for correspondence between the two groups. Multivariate ordered logistic regression analysis was used to identify factors that predicted efficacy, and the results are expressed as odds ratios (ORs) and 95% confidence intervals (CIs). Differences were considered

![Pie chart showing responders and nonresponders after naldemedine administration. Responder rate: 65.0%, 95% CI: 50.2%–79.7%](image)

**TABLE 3** Patient characteristics according to response

|                         | Responder (n = 26) | Nonresponder (n = 14) | Odds ratio | 95% CI    | p-value |
|-------------------------|--------------------|-----------------------|------------|-----------|---------|
| Sex Male/female         | 19/7               | 11/3                  | 0.74       | 0.15–3.46 | 0.99    |
| Age (years) <75 / ≥75   | 16/10              | 11/3                  | 0.43       | 0.09–1.95 | 0.31    |
| PS 0–2 / ≥3             | 10/16              | 6/8                   | 0.83       | 0.22–3.12 | 0.99    |
| Regular dose of opioids (mg/day, morphine equivalent) <30 / ≥30 | 9/17 | 5/9 | 0.95 | 0.24–3.71 | 0.99 |
| History of chemotherapy within 21 days prior to naldemedine administration Yes/No | 7/19 | 4/10 | 0.92 | 0.21–3.91 | 0.99 |
| History of abdominal surgery before starting naldemedine Yes/No | 3/23 | 5/9 | 0.23 | 0.04–1.19 | 0.10 |
| History of radiation to the abdomen and pelvic region before starting naldemedine Yes/No | 7/19 | 0/14 | NA | NA | 0.07 |
| Presence of diabetes mellitus Yes/No | 6/20 | 0/14 | NA | NA | 0.07 |
| Use of laxatives before starting naldemedine administration Yes/No | 23/3 | 13/1 | 0.58 | 0.05–6.26 | 0.99 |
| Use of laxatives after starting naldemedine administration Yes/No | 23/3 | 13/1 | 0.58 | 0.05–6.26 | 0.99 |

Abbreviations: CI, confidence interval; PS, performance status; NA, not applicable.

Note: Cisplatin + vinorelbine (cytotoxic drug) 6 days before the start of naldemedine.
Note: Carboplatin + paclitaxel (cytotoxic drug) 7 days before the start of naldemedine.
Note: Docetaxel+ramucirumab (cytotoxic drug) 5 days before the start of naldemedine.
Note: S-1 (cytotoxic drug) 7 days before the start of naldemedine.
Note: Gefitinib (tyrosine kinase inhibitor) 5 days after starting naldemedine.
Note: Nivolumab (immune checkpoint inhibitor) 1 day before the start of naldemedine pembrolizumab (immune checkpoint inhibitor) 3 days before the start of naldemedine.

Information on whether drug therapy was administered 7 days before and after naldemedine administration and the details of that chemotherapy are listed below as follows.
statistically significant at a two-tailed $p$-value $\leq 0.05$. All analyses were conducted using JMP software for Windows, version 11.0 (SAS Institute).

**RESULTS**

**Patient characteristics**

Of the 40 patients included in the analysis, 36 died due to disease progression. The patient characteristics are shown in Table 1. The median age was 71 years (range, 38–88 years), with 12 (30.0%) patients aged $\geq 75$ years. Additionally, 30 patients were male, and 10 were female. According to the Eastern Cooperative Oncology Group criteria, 10 patients (25.0%) had a PS of 0 or 1, 6 (15%) had a PS of 2, and 24 (60%) had a PS of 3 or 4, which was considered poor. In addition, 39 (97.5%) patients had lung cancer and one (2.5%) had malignant mesothelioma.

The use of opioids, laxatives, and antiemetic agents is shown in Table 2. The median regular opioid dose in oral morphine equivalents was 30 mg/day (range: 7.5–360 mg). Oxycodone was the most commonly used opioid in 22 patients (55.0%), followed by fentanyl in eight (20.0%). Moreover, 36 (90.0%) patients received concomitant laxatives, among whom 29 (80.6%) received magnesium oxide. Furthermore, 19 (47.5%) patients started naldemedine within 14 days of opioid initiation. Finally, 15 (37.5%) patients received concomitant antiemetic agents (regular or abbreviated use), among whom seven (46.6%) received metoclopramide.

**Treatment efficacy and safety**

The frequency of defecation of all 40 patients was observed for at least seven days before and after naldemedine administration. As shown in Figure 1, 26 (65%, 95% CI: 50.2%–79.7%) patients were responders, and 14 were nonresponders. Table 3 presents the patient characteristics according to the response. There was no statistical difference in patient background between the responders and nonresponders.

Next, we evaluated the change in the frequency of defecation before and after naldemedine administration in the following groups: all patients, only those who defecated less

**TABLE 4** Adverse events during naldemedine administration

| Adverse events | Grade 1 | Grade 2 | Grade 3 | Grade 4 |
|----------------|--------|--------|--------|--------|
| Diarrhea       | 8      | 1      | 2      | 0      |
| Abdominal pain | 0      | 0      | 0      | -      |
| Nausea         | 5      | 0      | 0      | -      |
| Vomiting       | 1      | 1      | 0      | 0      |
| Anorexia       | 8      | 0      | 0      | 0      |
| Fatigue        | 5      | 0      | 0      | -      |

*Adverse events were graded using the Common Terminology Criteria for Adverse Events version 5.0.*
Furthermore, in the overall population (n = 40), the median number of defe- cations in the seven days before and after naldemedine administration was 3 (range: 0–14) and 6 (range: 0–49), respectively; thus, the number of defe- cations increased significantly after naldemedine administration (p < 0.0001; Figure 2a). Then, we compared the frequency of defecation during the seven days before and after naldemedine administration in patients who had fewer than three defe- cations in the week before naldemedine administration (n = 17). The median number of defe- cations during the seven days before and after naldemedine administration was 1 (range: 0–2) and 4 (range: 0–11), respectively; thus, the number of defe- cations increased significantly after naldemedine administration (p = 0.0007; Figure 2b). Next, we compared the frequency of defecation according to the opioid dose. In patients that received <30 mg/day of morphine equivalent (n = 14), the median number of defe- cations in the seven days before and after naldemedine administration was 3 (range: 0–15) and 5 (range: 1–12), respectively; thus, the number of defe- cations did not increase significantly after naldemedine administration (p = 0.13; Figure 2c). Finally, the evaluation was limited to only patients that received ≥30 mg/day of morphine equivalent (n = 26). The median number of defe- cations in the seven days before and after naldemedine administration was 3 (range: 0–14) and 6.5 (range: 0–49), respectively; thus, the number of defe- cations increased significantly after naldemedine administration (p < 0.0001; Figure 2d).

The adverse events judged to be causally related to naldemedine administration are shown in Table 4. Diarrhea was the most common adverse event of any grade, occurring in 11 patients (27.5%), of which nine (81.8%) were grade 1 or 2. No patient experienced grade 4 or higher adverse events.

### Clinical factors influencing treatment response

Next, we analyzed the relationship between the efficacy of naldemedine and various clinical factors using multivariate logistic regression analysis (Table 5). We performed a multi- variate logistic analysis utilizing factors of clinical interest: age, PS, morphine equivalent regular opioid dose, history of chemotherapy within 21 days prior to naldemedine administration. Age, PS, morphine equivalent regular opioid dose, and history of chemotherapy within 21 days prior to naldemedine administration did not demonstrate a statistically significant difference in naldemedine efficacy.

### DISCUSSION

In this study, we evaluated the frequency of defecation and adverse events in thoracic cancer patients receiving opioids who were hospitalized for at least seven days before and after the start of naldemedine. In addition, we evaluated the effects of naldemedine and factors associated with these effects by assessing the change in the number of bowel movements before and after naldemedine initiation.

In the current analysis, 65.0% of the patients were responders, which is comparable to the responder rate in the COMPOSE-4 trial (71%) and that of a study on naloxegol (73%), a drug with the same peripherally acting μ-opioid receptor antagonist as naldemedine.

Furthermore, in the overall study population, those who defecated less than three times in the week before naldemedine treatment and those administered opioids with a morphine equivalent of ≥30 mg/day had statistically significant increases in defecation frequency after naldemedine treatment. Notably, a statistically significant improvement in the frequency of bowel movements was observed even in the group of patients judged to be constipated with fewer than three bowel move- ments in the week before naldemedine administration. Thus, this study confirmed that naldemedine might be effective even in thoracic cancer patients with OIC. Naldemedine is generally effective in the initial stage of opioid administra- tion owing to its pharmacological properties, as a low mor- phine equivalent dose is often administered in the initial stage of opioid treatment. However, there was no statistically significant increase in the frequency of bowel movements in patients that received <30 mg/day of morphine equivalent, which could be attributed to the small patient population (n = 13). It is necessary to study this phenomenon in larger sample sizes in the future. In the multivariate logistic regression analysis, none of the factors we evaluated (age, PS, morphine-equivalent opioid regular dose, or history of che- motherapy within 21 days before naldemedine administration) were found to impact the efficacy of naldemedine. These findings are consistent with previous reports, which identified no baseline patient characteristic that affect naldemedine efficacy in patients with OIC.

In the current analysis, 60.0% of patients had a PS ≥3, while the COMPOSE-4 and COMPOSE-5 randomized phase
III trials of naldemedine in cancer patients presenting with OIC excluded those with a PS ≥3.21 Thus, the efficacy and safety of naldemedine in most patients receiving the drug in clinical practice have not been evaluated in prospective clinical trials. Furthermore, although naldemedine is clinically administered to many outpatients, the defecation of such patients is impossible to calculate accurately; thus, the data were limited to inpatients. Inpatient data were more reliable as they were evaluated by healthcare providers, such as physicians, nurses, and pharmacists. Specifically, hospitalization for at least seven days before and after starting naldemedine was necessary to collect and evaluate sufficient data. In addition, because the patients included in this study were hospitalized for complications such as a poor PS or need for concomitant treatments, these findings should be interpreted with caution. This study had a large number of patients with poor PS (2, 3, 4) and shorter survival. Differences in patient backgrounds between current analysis and that of the COMPOSE-4 and COMPOSE-5 trials should be taken up in future studies.

Lung cancer has been reported to have a low rate of metastasis to the gastrointestinal tract at 2–5%.28,29 Trials involving various malignancies such as gastrointestinal cancers were similar to phase III prospective trials of naldemedine in terms of efficacy and adverse events. However, they carry a patient selection bias in that patients were enrolled if they had no gastrointestinal obstruction and could take medication orally. In terms of age, it has been reported that approximately 50% of patients with lung cancer are 70 years or older.30 Older adult patients generally have more complications and lower organ function than younger patients; therefore, treatment-related toxicities among older adult patients are a notable concern. Although older adult patients are generally excluded from prospective clinical trials, COMPOSE-4 and -5 included patients 20 years of age and older, and no upper age limit was specified.31 Additionally, a subgroup analysis in a phase III trial reported that naldemedine was generally effective and well-tolerated in patients ≥65 years with chronic noncancer-related pain.31 Consistent with this report, our study found no significant difference in naldemedine efficacy between patients older than 75 and those younger than 75, suggesting that naldemedine can be used effectively to treat older adults. In summary, patients with thoracic cancer do not require special considerations regarding the efficacy or adverse events of OIC treatment.

Regarding safety, diarrhea and abdominal pain were the commonly observed adverse events of naldemedine with incidence rates of 19.6%–39.7% and 1.7%, respectively, in prospective clinical trials of cancer patients with OIC.21,32 In our cohort, the incidence rate of diarrhea and abdominal pain was 27.5% and 0%, respectively, which was similar to that of the prospective phase III trials. Although our cohort included patients with a PS ≥3, as well as older adults (≥75 years), serious adverse events, including treatment-related death, were only observed in two cases (5.0%, grade 3 diarrhea), indicating that naldemedine can be safely administered to patients with thoracic cancer in clinical practice.

This study has several limitations. First, the cohort size was small; however, the number of patients was significant considering the specific inclusion criteria of patients with thoracic cancer who were hospitalized and whose defecation frequency was closely monitored by medical professionals for at least seven days before and after starting naldemedine. Second, due to the retrospective nature of the study, objective assessments, such as the Bristol stool form scale,33 bowel function index,34 and defecation diary, were not available. This limitation could reduce the validity of the data. Third, the decision to begin or discontinue naldemedine treatment was left to the discretion of each physician, allowing for differences due to subjectivity. Finally, the retrospective nature of the study made standardizing the effects of other treatments and concomitant medications impossible.

In conclusion, this study showed that the efficacy and safety of naldemedine for thoracic cancer patients in clinical practice—where the drug is often administered to older adult patients and those with a poor PS—were comparable with those of prospective studies. Thus, naldemedine may be effective and feasible for most thoracic cancer patients.

ACKNOWLEDGMENTS

We thank Hiromi Sakamoto, Tomoko Nakajima, and Mie Kotake, Kyoko Obayashi, and Shiro Koizuka for their assistance in preparing this manuscript. We also thank Editage (www.editage.jp) for English language editing.

CONFLICT OF INTEREST

The authors have no competing interests to declare that are relevant to the content of this article.

ORCID

Hisao Imai https://orcid.org/0000-0003-3097-4255
Kyoichi Kaira https://orcid.org/0000-0001-5548-7686

REFERENCES

1. Miller KD, Nogueira L, Mariotto AB, Rowland JH, Yabroff KR, Alfano CM, et al. Cancer treatment and survivorship statistics. 2019. CA Cancer J Clin. 2019;69(5):363–85. https://doi.org/10.3322/caac.21565
2. Di Maio M, Gridelli C, Gallo C, Manzione I, Brancaccio L, Barbera S, et al. Prevalence and management of pain in Italian patients with advanced non-small-cell lung cancer. Br J Cancer. 2004;90(12):2288–96. https://doi.org/10.1038/sj.bjc.6601810
3. Fallon M, Giusti R, Aielli F, Hoskin P, Rolke R, Sharma M, et al. Management of cancer pain in adult patients: ESMO clinical practice guidelines. Ann Oncol. 2018;29(Suppl 4):iv166–91. https://doi.org/10.1093/annonc/mdy152
4. Jara C, Del Barco S, Grávalos C, Hoyos S, Hernández B, Muñoz M, et al. SEOM clinical guideline for treatment of cancer pain (2017). Clin Transl Oncol. 2018;20(1):97–107. https://doi.org/10.1007/s12094-017-1791-2
5. Wiffen PJ, Wee B, Moore RA. Oral morphine for cancer pain. Cochrane Database Syst Rev. 2016;4:CD003868.
6. Wiffen PJ, Wee B, Derry S, Bell RF, Moore RA. Opioids for cancer pain—an overview of Cochrane reviews. Cochrane Database Syst Rev. 2017;7:CD012592. https://doi.org/10.1002/14651858.CD012592.pub2
7. Bell TJ, Panchal SJ, Miaskowski C, Bolge SC, Milanova T, Williamson R. The prevalence, severity, and impact of opioid-induced
bowel dysfunction: results of a US and European patient survey (PROBE 1). Pain Med. 2009;10(1):35–42. https://doi.org/10.1111/j.1526-4377.2008.00495.x

8. Ishihara M, Ikesue H, Matsuana G, SueMaru K, Kitaichi K, Suetsugu K, et al. A multi-institutional study analyzing effect of prophylactic medication for prevention of opioid-induced gastrointestinal dysfunction. Clin J Pain. 2012;28(3):373–81. https://doi.org/10.1097/AJP.0b013e318237d626

9. Wiffen PJ, Derry S, Moore RA. Impact of morphine, fentanyl, oxycodone or codeine on patient consciousness, appetite and thirst when used to treat cancer pain. Cochrane Database Syst Rev. 2014;5(5):CD011056. https://doi.org/10.1002/14651858.CD011056.pub2

10. Laugsand EA, Kaasa S, Klepstad P. Management of opioid-induced nausea and vomiting in cancer patients: systematic review and evidence-based recommendations. Palliat Med. 2011;25(5):442–53. https://doi.org/10.1177/0269216311404273

11. Coyne KS, Margolis MK, Yeomans K, King FR, Chavoshi S, Payne KA, et al. Opioid-induced constipation among patients with chronic noncancer pain in the United States, Canada, Germany, and the United Kingdom: laxative use, response, and symptom burden over time. Pain Med. 2015;16(8):1551–65. https://doi.org/10.1111/pmc.12724

12. Smorning R, Wallenhorst T, Bouji P, Lethueille J, Le Tulzo Y, Tadié JM, et al. Constipation is independently associated with delirium in critically ill ventilated patients. Intensive Care Med. 2016;42(1):126–7. https://doi.org/10.1007/s00134-015-4050-4

13. Gupta S, Patel H, Scopel J, Mody RR. Impact of constipation on opioid therapy management among long-term opioid users, based on a patient survey. J Opioid Manag. 2015;11(4):325–38. https://10.5055/jom.2015.02828

14. Mearin F, Lacy BE, Chang L, Chey WD, Lemoj AJ, Simren M, et al. Bowel disorders. Gastroenterology. 2016;150:1393–1407.e5. https://doi.org/10.1053/j.gastro.2016.02.031

15. Brown TJ, Keshvani N, Gupta A, Yang H, Agraval D, Le TG, et al. Rates of appropriate laxative prophylaxis for opioid-induced constipation in veterans with lung cancer: a retrospective cohort study. Support Care Cancer. 2020;28(11):5313–21. https://doi.org/10.1007/s00520-020-05364-6

16. Tokoro A, Imai H, Fumita S, Harada T, Noriyuki T, Gamoh M, et al. Incidence of opioid-induced constipation in Japanese patients with cancer pain: a prospective observational cohort study. Cancer Med. 2019;8(10):4883–91. https://doi.org/10.1002/cam4.2341

17. Imai H, Fumita S, Harada T, Noriyuki T, Gamoh M, Okamoto M, et al. Opioid-induced constipation in patients with cancer pain in Japan (OIC-J study): a post hoc subgroup analysis of patients with lung cancer. Jpn J Clin Oncol. 2021;51(3):444–50. https://doi.org/10.1093/jjco/hyaa186

18. Poulsen JL, Brock C, Olesen AE, Nilsson M, Drewes AM. Clinical potential of naloxegol in the management of opioid-induced bowel dysfunction. Clin Exp Gastroenterol. 2014;7:345–58. https://doi.org/10.2147/CEG.S2097

19. Nilsson M, Poulsen JL, Brock C, Sandberg TH,Gram M, Frokjer JB, et al. Opioid-induced bowel dysfunction in healthy volunteers assessed with questionnaires and MRI. Eur J Gastroenterol Hepatol. 2016;28(5):514–21. https://doi.org/10.1097/MEG.0000000000000574

20. Blair HA. Naldemedine: a review in opioid-induced constipation. Drugs. 2019;79(11):1241–7. https://doi.org/10.1007/s40265-019-01160-7

21. Katakami N, Harada T, Murata T, Shinozaki K, Tsutsumi M, Yokota T, et al. Randomized phase III and extension studies of Naldemedine in patients with opioid-induced constipation and cancer. J Clin Oncol. 2017;35(34):3859–66. https://doi.org/10.1200/JCO.2017.73.0853

22. Katakami N, Harada T, Murata T, Shinozaki K, Tsutsumi M, Yokota T, et al. Randomized phase III and extension studies: efficacy and impacts on quality of life of naldemedine in subjects with opioid-induced constipation and cancer. Ann Oncol. 2018;29(6):1461–7. https://doi.org/10.1093/annonc/mdy118

23. Hiruta E, Fujita Y, Imai H, Masuno T, Yamazaki S, Tanaka H, et al. Real-world patient characteristics and treatment patterns of Naldemedine for the treatment of opioid-induced constipation in patients with cancer: a multicenter retrospective chart review study. Medicina (Kaunas). 2021;57(11). https://doi.org/10.3390/medicina57111233

24. Nishiba H, Imai H, Fujita Y, Hiruta E, Masuno T, Yamazaki S, et al. Efficacy and safety of Naldemedine for patients with cancer with opioid-induced constipation in clinical practice: a real-world retrospective study. J Clin Med. 2022;11(9). https://doi.org/10.3390/jcm11092672

25. Lemaire A, Pointreau Y, Narciso B, Piloquet FX, Braniste V, Sabate JM. Effectiveness of naloxegol in patients with cancer pain suffering from opioid-induced constipation. Support Care Cancer. 2021;29(12):7577–86. https://doi.org/10.1007/s00520-021-06299-2

26. Kubota R, Fukumura K, Wajima T. Population pharmacokinetics and exposure–response relationships of Naldemedine. Pharm Res. 2018;35(11):225. https://doi.org/10.1007/s11095-018-2501-7

27. Osaka I, Ishiki H, Yokota T, Tada Y, Sato H, Okamoto M, et al. Safety and efficacy of naldemedine for patients with opioid-induced constipation: a pooled, subgroup analysis of two randomised controlled studies. ESMO Open. 2019;4(4):e000527. https://doi.org/10.1136/esmoopen-2019-000527

28. Gilg MM, Gröchenig HP, Schlemmer A, Eherer A, Högencuer A, Langner C. Secondary tumors of the GI tract: origin, histology, and endoscopic findings. Gastrointest Endosc. 2018;88(1):151–158.e1. https://doi.org/10.1016/j.gie.2018.02.019

29. Kaila V, Jain R, Lager DJ, Jensen P, Feldman M. Frequency of metastasis to the gastrointestinal tract determined by endoscopy in a community-based gastroenterology practice. Proc (Bayl Univ Med Cent). 2021;34(6):658–63. https://doi.org/10.1080/08998200.2021.1936261

30. Siegel RL, Miller KD. Jemal a (2018) cancer statistics. CA Cancer J Clin. 2018;68(1):7–30. https://doi.org/10.3322/caac.21442

31. Wild J, Webster L, Yamada T, Hale M. Safety and efficacy of Naldemedine for the treatment of opioid-induced constipation in patients with chronic non-cancer pain receiving opioid therapy: a subgroup analysis of patients ≥ 65 years of age: ≥ 65 years of age. Drugs Aging. 2020;37(4):271–9. https://doi.org/10.1007/s40266-020-00753-2

32. Katakami N, Oda K, Tauchi K, Nakata K, Shinozaki K, Yokota T, et al. Phase IIb, randomized, double-blind, placebo-controlled study of Naldemedine for the treatment of opioid-induced constipation in patients with cancer. J Clin Oncol. 2017;35(17):1921–8. https://doi.org/10.1200/JCO.2016.70.8453

33. Müller-Lissner S, Bassotti G, Coffin B, Drewes AM, Breivik H, Eisenberg E, et al. Opioid-induced constipation and bowel dysfunction: a clinical guideline. Pain Med. 2017;18(10):1837–45. https://doi.org/10.1093/pm/pnw255

34. Rentz AM, Yu R, Müller-Lissner S, Leyendecker P. Validation of the bowel function index to detect clinically meaningful changes in opioid-induced constipation. J Med Econ. 2009;12(4):371–83. https://doi.org/10.3390/medicina57111233

SUPPORTING INFORMATION
Additional supporting information can be found online in the Supporting Information section at the end of this article.

How to cite this article: Imai H, Fujita Y, Hiruta E, Masuno T, Yamazaki S, Tanaka H, et al. A retrospective study of the efficacy and safety of naldemedine for opioid-induced constipation in thoracic cancer patients. Thorac Cancer. 2022;13(16):2301–8. https://doi.org/10.1111/1759-7714.14557